慢性開閉創の治療におけるネオテリウムftの有効性の評価
慢性開閉創傷の治癒におけるネオテリウムftの有効性の評価:ランダム化比較多施設試験
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
調査の概要
詳細な説明
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Angelina Ferguson, DNP
- 電話番号:(985) 629-4013
- メール:info@sygnola.com
研究連絡先のバックアップ
- 名前:Sarah Moore, MBE
- 電話番号:(985) 629-4013
- メール:info@sygnola.com
研究場所
-
-
Louisiana
-
Denham Springs、Louisiana、アメリカ、70726
- 募集
- MedCentris of Denham Springs
-
主任研究者:
- Monique Consoer, NP
-
コンタクト:
- Tabatha Yent
- メール:tabatha.yent@medcentris.com
-
Hammond、Louisiana、アメリカ、70403
- 募集
- MedCentris of Hammond
-
主任研究者:
- Chris Keaton, NP
-
コンタクト:
- Chelsea Smith, RN
- メール:Chelsea.smith@medcentris.com
-
コンタクト:
- Melanie Knox, LPN
- メール:Melanie.knox@medcentris.com
-
Lafayette、Louisiana、アメリカ、70507
- 完了
- MedCentris of Carencro
-
Leesville、Louisiana、アメリカ、71146
- 募集
- MedCentris of Leesville
-
主任研究者:
- Stefanie Corley, FNP
-
コンタクト:
- Brandi Shuff
- メール:Brandi.shuff@medcentris.com
-
Many、Louisiana、アメリカ、71449
- 募集
- MedCentris of Many
-
主任研究者:
- Stefanie Corley, FNP
-
コンタクト:
- Brandi Shuff
- メール:Brandi.Shuff@medcentris.com
-
Marksville、Louisiana、アメリカ、71351
- 募集
- MedCentris of Marksville
-
主任研究者:
- Averie Rachal, FNP
-
コンタクト:
- Laura Whittington
- メール:Laura.whittington@medcentris.com
-
Metairie、Louisiana、アメリカ、70001
- 募集
- MedCentris of Metairie
-
コンタクト:
- Ninya Powell
- メール:ninya.powell@medcentris.com
-
主任研究者:
- Sarah Logrande, NP
-
Minden、Louisiana、アメリカ、71055
- 募集
- MedCentris of Minden
-
主任研究者:
- Taheera Forbes, NP
-
コンタクト:
- Brianna Thompas
- メール:brianna.thompson@medcentris.com
-
Monroe、Louisiana、アメリカ、71201
- まだ募集していません
- MedCentris of Monroe
-
主任研究者:
- Libbi Trawick, NP
-
コンタクト:
- Tiffany Dew
- メール:Tiffany.dew@medcentris.com
-
Slidell、Louisiana、アメリカ、70458
- 募集
- MedCentris of Slidell
-
主任研究者:
- Katie Schloegel, FNP
-
コンタクト:
- Donyille Singletary, RN
- 電話番号:985-602-1215
- メール:Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville、Mississippi、アメリカ、39540
- 完了
- MedCentris of D'iberville
-
McComb、Mississippi、アメリカ、39648
- 完了
- MedCentris of McComb
-
Natchez、Mississippi、アメリカ、39120
- 完了
- MedCentris of Natchez
-
Southaven、Mississippi、アメリカ、38671
- 募集
- MedCentris of Southaven
-
主任研究者:
- Carlene McAllister, NP
-
コンタクト:
- De'Nyia Woods
- メール:denyia.woods@medcentris.com
-
-
New York
-
Brooklyn、New York、アメリカ、11234
- 募集
- Northeast Podiatry Consultant
-
コンタクト:
- Thomas Hayes
- メール:thomas@simonfootandankle.com
-
主任研究者:
- David Simon, DPM, FACFAS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
実験的:Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Complete Wound Closure
時間枠:1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage Wound Area Change
時間枠:1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
時間枠:Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Follow-Up Closure
時間枠:2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
時間枠:Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
時間枠:1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
協力者と研究者
協力者
捜査官
- スタディディレクター:Angelina Ferguson, DNP、SygNola, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HEAL
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。